Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia

• Proportion of patients with mutated and unmutated IgVH genes
• Toxicity
• Correlation of pretreatment clinical and biological characteristics with response, TT2T, and overall survival (OS) in high-risk patients
• Correlation of pretreatment clinical and biological characteristics with time to first treatment (as measured from study registration date) in low-risk patients
• Distribution of time to first treatment (as measured from study registration date) and OS in low-risk patients
• Description of patterns of resistance (in terms of clonal evolution) in relapsed patients
• PCR status (positive/negative) at end of treatment as a predictor of TT2T and OS

RATIONALE: Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Giving fludarabine together with rituximab may kill more cancer cells. Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient. It is not yet known whether giving fludarabine together with rituximab early is more effective than giving fludarabine and rituximab after observation in treating chronic lymphocytic leukemia.

PURPOSE: This randomized phase III trial is studying fludarabine and rituximab to compare how well they work when given early or after observation in treating patients with previously untreated chronic lymphocytic leukemia.

OBJECTIVES:

Primary

• To determine if early treatment with chemoimmunotherapy comprising fludarabine phosphate and rituximab extends the time to second treatment in patients with genetically high-risk (unmutated IgV_H), asymptomatic, previously untreated chronic lymphocytic leukemia (CLL).
• To determine the time to disease progression that would warrant second treatment.
• To determine overall survival.

Secondary

• To measure the proportion of patients with asymptomatic, previously untreated CLL who have mutated and unmutated IgV_H genes.
• To determine the differences in acute and chronic toxicity of administering chemoimmunotherapy early to patients with genetically high-risk CLL compared to waiting until symptoms develop.
• To determine the effect of select pretreatment clinical and biological characteristics (such as interphase cytogenetic abnormalities, ZAP-70 expression, and p53 dysfunction [primary and secondary]) on response, time to second treatment, and overall survival of patients with genetically high-risk CLL randomized to early treatment.
• To determine the effect of select pretreatment clinical and biological characteristics (such as interphase cytogenetic abnormalities, ZAP-70 expression, and p53 dysfunction) on response, time to first and second treatments, and overall survival of patients with genetically high-risk CLL randomized to standard treatment (observation until symptoms occur).
• To describe the natural history of patients with genetically low-risk (mutated IgV_H genes), asymptomatic, previously untreated CLL, in terms of time to initial treatment, response, progression, and survival.
• To determine the effect of select pretreatment characteristics on time to first treatment, response, progression, and survival of patients with genetically low-risk CLL.
• To correlate patterns of resistance that emerge in patients with unmutated IgV_H genes who have relapsing or refractory CLL following receipt of chemoimmunotherapy with clonal evolution, including acquisition of high-risk karyotype abnormalities, p53 mutations, p53 dysfunction (primary and secondary), altered mRNA and protein expression related to treatment resistance, DNA mutations, microRNA gene expression, and methylation changes.
• To determine whether highly sensitive flow cytometry negativity at completion of therapy in patients randomized to early treatment is an effective surrogate marker for prolonged time to second treatment, overall survival, and other clinical benefits.
• To collect demographic data on familial CLL in newly diagnosed patients participating on this study.

OUTLINE: This is a multicenter study.

• Genetically high-risk disease: Patients are stratified according to age (< 50 years vs 50 to 70 years vs > 70 years) and presence of the high-risk genetic feature [del(11)(q22.3) or del(17)(p13.1)] by FISH (yes vs no). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
  • Arm II: Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
• Genetically low-risk disease: Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.

Patients undergo blood sample collection periodically for correlative studies.

After finishing treatment, patients are followed periodically for up to 25 years.

• Biological: rituximab
  Given IV over 4 hours
• Drug: fludarabine phosphate
  Given IV over 30 minutes

• Experimental: Arm I
  Patients receive rituximab IV over 4 hours on days 1, 3, and 5 of week 1 and then on day 1 of weeks 5, 9, 13, 17, and 21. Patients also receive fludarabine phosphate IV over 30 minutes on days 1-5 of weeks 1, 5, 9, 13, 17, and 21. After completion of chemoimmunotherapy, patients are followed every 3 months until disease progression. At the time of disease progression, patients receive retreatment with chemoimmunotherapy as above or another treatment regimen.
  Interventions:

  • Biological: rituximab
  • Drug: fludarabine phosphate
• Active Comparator: Arm II
  Patients are followed every 3 months until disease progression. At the time of disease progression, patients receive rituximab and fludarabine phosphate as in arm I. Patients are then followed every 3 months until second disease progression. Patients with a second disease progression receive retreatment with chemoimmunotherapy as above or another treatment regimen.
  Interventions:

  • Biological: rituximab
  • Drug: fludarabine phosphate

DISEASE CHARACTERISTICS:

• Clinical and immunophenotypic evidence of B-cell chronic lymphocytic leukemia (CLL) diagnosed within the past 6 months AND meets the following criteria:

  • An absolute lymphocytosis of > 5,000/μL
  • Morphologically, the lymphocytes must appear mature with < 55% prolymphocytes

  • Local institution lymphocyte phenotype must reveal a predominant B-cell monoclonal population sharing a B-cell marker (CD19, CD20, CD23) with the CD5 antigen, in the absence of other pan-T-cell markers

    • B-cells must be monoclonal with regard to expression of either κ or λ and have surface immunoglobulin expression of low density
    • Patients with bright surface immunoglobulin levels must have CD23 coexpression and absence of t(11;14) on interphase cytogenetics or have negative tumor protein staining for cyclin D1
• Low-risk category (i.e., only stages 0 or I) of the modified three-stage Rai staging system

• No evidence of active or progressive disease as demonstrated by any of the following:

  • Massive or progressive splenomegaly and/or lymphadenopathy that requires therapy
  • Progressive lymphocytosis with an increase of > 50% over a 2-month period or an anticipated doubling time of less than 6 months
  • Presence of weight loss > 10% over the preceding 6-month period
  • Grade 2 or 3 fatigue
  • Fevers > 100.5°F and/or night sweats for greater than 2 weeks without evidence of infection
  • Development of anemia (hemoglobin < 11 g/dL) or thrombocytopenia (platelets < 100,000/μL)

• Must have undergone IgV_H mutation testing and be classified according to the following:

  • Genetically low-risk disease

    • IgV_H mutated
    • Less than 98% IgV_H homology

  • Genetically high-risk disease

    • IgV_H unmutated
    • At least 98% IgV_H homology

PATIENT CHARACTERISTICS:

• Performance status 0-1
• Creatinine ≤ 1.5 times upper limit of normal
• No HIV disease
• Not pregnant or nursing
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• No prior therapy for CLL, including corticosteroids for autoimmune complications that have developed since the initial diagnosis of CLL
• No concurrent hormones or other chemotherapy except for steroids for hypersensitivity reactions or new adrenal failure (chronic requirement for steroids is an exclusion criterion for this study) or hormones for non-disease-related conditions (e.g., insulin for diabetes)
• No concurrent palliative radiotherapy